Emily Ajit-Roger, Keith Richardson, Alex Marcin Mlynarek, Nader Sadeghi, Michael P Hier, Marco A Mascarella
{"title":"18F-FDG PET/CT监测唾液腺癌：系统回顾和荟萃分析。","authors":"Emily Ajit-Roger, Keith Richardson, Alex Marcin Mlynarek, Nader Sadeghi, Michael P Hier, Marco A Mascarella","doi":"10.1002/lary.32003","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the diagnostic accuracy of 18F-FDG-PET/CT compared to conventional imaging modalities (CIM) to detect recurrence of primary salivary gland cancers (SGCs).</p><p><strong>Data sources: </strong>Review performed on December 26, 2024, using Embase, CINHAL, MEDLINE, and PubMed.</p><p><strong>Review methods: </strong>Two blinded reviewers selected studies reporting diagnostic accuracy of PET/CT in identifying locoregional recurrence and/or metastasis in patients with SGCs. The analysis was performed adhering to PRISMA guidelines using R 4.3.3. Pooled analysis with 95% confidence intervals (CI) were analyzed.</p><p><strong>Results: </strong>A total of 12 studies were retained from the systematic review, including 264 patients evaluated in the meta-analysis. For local recurrence, there was a pooled sensitivity of 0.86 (95% CI 0.73-0.93) and a pooled specificity of 0.95 (95% CI 0.92-0.97) for PET/CT, and a pooled sensitivity of 0.89 (95% CI 0.80-0.94) and a pooled specificity of 0.91 (95% CI 0.79-0.97) for CIM (p = 0.90). For regional metastasis, there was a pooled sensitivity of 0.90 (95% CI 0.73-0.97) and a pooled specificity of 0.96 (95% CI 0.92-0.98) for PET/CT, and a pooled sensitivity of 0.80 (95% CI 0.62-0.91) and a pooled specificity of 0.95 (0.90-0.98) for CIM (p = 0.26). For distant metastasis, there was a pooled sensitivity of 0.96 (95% CI 0.90-0.99) and a pooled specificity of 0.95 (95% CI 0.85-0.98) for PET/CT, and a pooled sensitivity of 0.80 (95% CI 0.71-0.86) and a pooled specificity of 0.97 (95% CI 0.87-0.99) for CIM (p = 0.018).</p><p><strong>Conclusions: </strong>18F-FDG-PET/CT imaging is accurate for the detection of SGC recurrence, particularly for the detection of regional and distant metastases.</p><p><strong>Level of evidence: </strong>Not applicable Laryngoscope, 2025.</p>","PeriodicalId":49921,"journal":{"name":"Laryngoscope","volume":" ","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"18F-FDG PET/CT for Surveillance in Salivary Gland Cancers: A Systematic Review and Meta-Analysis.\",\"authors\":\"Emily Ajit-Roger, Keith Richardson, Alex Marcin Mlynarek, Nader Sadeghi, Michael P Hier, Marco A Mascarella\",\"doi\":\"10.1002/lary.32003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To evaluate the diagnostic accuracy of 18F-FDG-PET/CT compared to conventional imaging modalities (CIM) to detect recurrence of primary salivary gland cancers (SGCs).</p><p><strong>Data sources: </strong>Review performed on December 26, 2024, using Embase, CINHAL, MEDLINE, and PubMed.</p><p><strong>Review methods: </strong>Two blinded reviewers selected studies reporting diagnostic accuracy of PET/CT in identifying locoregional recurrence and/or metastasis in patients with SGCs. The analysis was performed adhering to PRISMA guidelines using R 4.3.3. Pooled analysis with 95% confidence intervals (CI) were analyzed.</p><p><strong>Results: </strong>A total of 12 studies were retained from the systematic review, including 264 patients evaluated in the meta-analysis. For local recurrence, there was a pooled sensitivity of 0.86 (95% CI 0.73-0.93) and a pooled specificity of 0.95 (95% CI 0.92-0.97) for PET/CT, and a pooled sensitivity of 0.89 (95% CI 0.80-0.94) and a pooled specificity of 0.91 (95% CI 0.79-0.97) for CIM (p = 0.90). For regional metastasis, there was a pooled sensitivity of 0.90 (95% CI 0.73-0.97) and a pooled specificity of 0.96 (95% CI 0.92-0.98) for PET/CT, and a pooled sensitivity of 0.80 (95% CI 0.62-0.91) and a pooled specificity of 0.95 (0.90-0.98) for CIM (p = 0.26). For distant metastasis, there was a pooled sensitivity of 0.96 (95% CI 0.90-0.99) and a pooled specificity of 0.95 (95% CI 0.85-0.98) for PET/CT, and a pooled sensitivity of 0.80 (95% CI 0.71-0.86) and a pooled specificity of 0.97 (95% CI 0.87-0.99) for CIM (p = 0.018).</p><p><strong>Conclusions: </strong>18F-FDG-PET/CT imaging is accurate for the detection of SGC recurrence, particularly for the detection of regional and distant metastases.</p><p><strong>Level of evidence: </strong>Not applicable Laryngoscope, 2025.</p>\",\"PeriodicalId\":49921,\"journal\":{\"name\":\"Laryngoscope\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2025-01-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Laryngoscope\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/lary.32003\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Laryngoscope","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/lary.32003","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
摘要
目的：评价18F-FDG-PET/CT对原发性唾液腺癌（SGCs）复发的诊断准确性，并与常规影像学（CIM）进行比较。数据来源：于2024年12月26日进行的综述，使用Embase， CINHAL， MEDLINE和PubMed。回顾方法：两名盲法回顾者选择了报道PET/CT在识别SGCs患者局部复发和/或转移方面诊断准确性的研究。按照PRISMA指南使用r4.3.3进行分析。采用95%置信区间（CI）进行合并分析。结果：系统评价共保留了12项研究，包括264例在meta分析中评估的患者。对于局部复发，PET/CT的合并敏感性为0.86 (95% CI 0.73-0.93)，合并特异性为0.95 (95% CI 0.92-0.97)， CIM的合并敏感性为0.89 (95% CI 0.80-0.94)，合并特异性为0.91 (95% CI 0.79-0.97) （p = 0.90）。对于区域转移，PET/CT的合并敏感性为0.90 (95% CI 0.73-0.97)，合并特异性为0.96 (95% CI 0.92-0.98)， CIM的合并敏感性为0.80 (95% CI 0.62-0.91)，合并特异性为0.95 (0.90-0.98)（p = 0.26）。对于远处转移，PET/CT的合并敏感性为0.96 (95% CI 0.90-0.99)，合并特异性为0.95 (95% CI 0.85-0.98)， CIM的合并敏感性为0.80 (95% CI 0.71-0.86)，合并特异性为0.97 (95% CI 0.87-0.99) （p = 0.018）。结论：18F-FDG-PET/CT成像对SGC复发的检测是准确的，特别是对局部和远处转移的检测。证据等级：不适用喉镜，2025。
18F-FDG PET/CT for Surveillance in Salivary Gland Cancers: A Systematic Review and Meta-Analysis.
Objective: To evaluate the diagnostic accuracy of 18F-FDG-PET/CT compared to conventional imaging modalities (CIM) to detect recurrence of primary salivary gland cancers (SGCs).
Data sources: Review performed on December 26, 2024, using Embase, CINHAL, MEDLINE, and PubMed.
Review methods: Two blinded reviewers selected studies reporting diagnostic accuracy of PET/CT in identifying locoregional recurrence and/or metastasis in patients with SGCs. The analysis was performed adhering to PRISMA guidelines using R 4.3.3. Pooled analysis with 95% confidence intervals (CI) were analyzed.
Results: A total of 12 studies were retained from the systematic review, including 264 patients evaluated in the meta-analysis. For local recurrence, there was a pooled sensitivity of 0.86 (95% CI 0.73-0.93) and a pooled specificity of 0.95 (95% CI 0.92-0.97) for PET/CT, and a pooled sensitivity of 0.89 (95% CI 0.80-0.94) and a pooled specificity of 0.91 (95% CI 0.79-0.97) for CIM (p = 0.90). For regional metastasis, there was a pooled sensitivity of 0.90 (95% CI 0.73-0.97) and a pooled specificity of 0.96 (95% CI 0.92-0.98) for PET/CT, and a pooled sensitivity of 0.80 (95% CI 0.62-0.91) and a pooled specificity of 0.95 (0.90-0.98) for CIM (p = 0.26). For distant metastasis, there was a pooled sensitivity of 0.96 (95% CI 0.90-0.99) and a pooled specificity of 0.95 (95% CI 0.85-0.98) for PET/CT, and a pooled sensitivity of 0.80 (95% CI 0.71-0.86) and a pooled specificity of 0.97 (95% CI 0.87-0.99) for CIM (p = 0.018).
Conclusions: 18F-FDG-PET/CT imaging is accurate for the detection of SGC recurrence, particularly for the detection of regional and distant metastases.
Level of evidence: Not applicable Laryngoscope, 2025.
期刊介绍：
The Laryngoscope has been the leading source of information on advances in the diagnosis and treatment of head and neck disorders since 1890. The Laryngoscope is the first choice among otolaryngologists for publication of their important findings and techniques. Each monthly issue of The Laryngoscope features peer-reviewed medical, clinical, and research contributions in general otolaryngology, allergy/rhinology, otology/neurotology, laryngology/bronchoesophagology, head and neck surgery, sleep medicine, pediatric otolaryngology, facial plastics and reconstructive surgery, oncology, and communicative disorders. Contributions include papers and posters presented at the Annual and Section Meetings of the Triological Society, as well as independent papers, "How I Do It", "Triological Best Practice" articles, and contemporary reviews. Theses authored by the Triological Society’s new Fellows as well as papers presented at meetings of the American Laryngological Association are published in The Laryngoscope.
• Broncho-esophagology
• Communicative disorders
• Head and neck surgery
• Plastic and reconstructive facial surgery
• Oncology
• Speech and hearing defects
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
